Multiple Myeloma
Yttrium Y 90 anti-CD45 monoclonal antibody BC8 + Chemo + TDI before Transplant for Multiple Myeloma (2450)
A Phase I Study of 90Y-BC8-DOTA monoclonal antibody, Fludarabine and TBI Followed by HLA-Matched, Allogeneic Peripheral Blood Stem Cell Transplant for the Treatment of Multiple Myeloma
Investigator: Bill Bensinger, MD; Conditions: Refractory Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma; Status: Recruiting; Study ID: NCT01503242
An Open Label, Dose Escalation, Phase 1 Study Evaluating the Safety and Tolerability of Weekly Dosing of the Oral Form of MLN9708, a Second Generation Proteasome Inhibitor, in Adult patients with Relapsed and Refractory Multiple Myeloma
Investigator: Bill Bensinger, MD; Conditions: Multiple Myeloma (MM); Status: Recruiting; Study ID: NCT00963820
A Phase 1/2 Study Of Arry-520 In Patients With Relapsed Or Refractory Multiple Myeloma
Investigator: Bill Bensinger, MD; Conditions: Multiple Myeloma; Status: Recruiting; Study ID: NCT00821249
A Multi-Center Phase I, Open-Label, Dose-Finding Pilot Study of the Combination of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Investigator: William Bensinger, MD; Conditions: Multiple Myeloma; Status: Recruiting; Study ID: NCT01464034
A Phase 1b, Open-label, Multicenter Study of (BMS-936564) in Combination With Lenalidomide (Revlimid) Plus Low-dose Dexamethasone, or With Bortezomib (Velcade) Plus Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Investigator: Pamela Becker, MD, PhD; Conditions: Multiple Myeloma; Status: Recruiting; Study ID: NCT01359657
Join Us On